| 摘要 |
<p>The invention relates to liposomal formulations containing a rifamycin and/or a hydrophobic derivative as a pharmacological active substance, for clinical use, comprising pharmacological active substance/lipid ratios of 1 mole per 10 to 40 moles, lipidic compositions made by mixtures of glycerophospholipids of saturated or unsaturated acyl chains, with cholesterol and charged molecules of lipidic nature or not. The liposomal rifamycin presents a stability in saline and in human serum higher than 50 %, incorporation efficiencies up to 95 %, intraliposomal concentration of at least 1 mg/ml and toxicity lower compared to the free pharmacological active substance. The invention also refers to a process for the preparation of liposomal formulations comprising solving the pharmacological active substance and the other components in appropriate solvents, lyophilization or not and rehydration of the lyophilized or resulting mixture.</p> |
